Bayer and Onyx seek EU approval for kidney cancer drug
13th Sep 2005, 06:46 GMT
Bayer Pharmaceuticals and Onyx Pharmaceuticals have submitted a marketing authorization application to the European Medicines Agency to market sorafenib within the EU for the treatment of advanced kidney cancer.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol